Stockholm, Sweden, September 22, 2016 / B3C newswire / -- Nuevolution AB (publ) (NUE.ST) will today present preclinical and preliminary toxicology data from its BET BD1 program at Discovery on Target 2016 (DoT 2016) in Boston, MA, USA.
Jimmi G. Seitzberg, Project Manager, Nuevolution, will give an oral presentation reporting the key findings from the poster “NUE7770 - A BET-BD1 selective chemical probe with potent cellular and in vivo anti-inflammatory activity”, also including preliminary data from the first comparative animal toxicology study with NUE7770, selective BET BD1 inhibitor.
The preliminary data from a two-week mouse toxicology study with Nuevolution’s selective BET inhibitor NUE7770 showed no mortality and no loss in body weight even at high doses of the compound, whereas the non-selective BET control compound, JQ1, showed a high mortality already at lower doses.
The final conclusion from this toxicology study is not yet available as further studies still are ongoing. A full characterisation and conclusion from this comparative animal toxicology study will be available in the fourth quarter 2016.
NUE7770 is also being tested in mouse models of Systemic Lupus Erythematosus (SLE) and Idiopathic Lung Fibrosis (IPF), severe inflammatory diseases. Data from these studies will be reported later in 2016.
About bromodomain proteins
BET bromodomain proteins play an important role in regulation of gene expression, which thereby affect inflammatory responses and the ability of cancer cells to sustain growth and survive. The human proteome comprises 46 bromodomain-containing proteins, many of which are thought to be involved in cancer, inflammation and cardiovascular disease.
About Nuevolution
Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.
Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was sent for publication on Thursday 22 September 2016, 18:10 (CEST).
Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ).
Contacts
Thomas Franch, CSO
+45 7020 0987
This email address is being protected from spambots. You need JavaScript enabled to view it.
Henrik D. Simonsen, CFO
+45 3913 0947
This email address is being protected from spambots. You need JavaScript enabled to view it.